Scholarlink

<p>Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8<sup>+</sup> T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Kelsey R. Monson,
  • Robert Ferguson,
  • Joanna E. Handzlik,
  • Leah Morales,
  • Jiahan Xiong,
  • Vylyny Chat,
  • Sasha Dagayev,
  • Alireza Khodadadi-Jamayran,
  • Danny Simpson,
  • Esther Kazlow,
  • Anabelle Bunis,
  • Chaitra Sreenivasaiah,
  • Milad Ibrahim,
  • Iryna Voloshyna,
  • Wouter Ouwerkerk,
  • Rosalie M. Luiten,
  • Mariaelena Capone,
  • Gabriele Madonna,
  • Yuting Lu,
  • Yongzhao Shao,
  • Anna Pavlick,
  • Michelle Krogsgaard,
  • Janice Mehnert,
  • Hao Tang,
  • Sonia Dolfi,
  • Daniel Tenney,
  • John B. A. G. Haanen,
  • Thomas F. Gajewski,
  • F. Stephen Hodi,
  • Keith T. Flaherty,
  • Kasey Couts,
  • William Robinson,
  • Igor Puzanov,
  • Marc S. Ernstoff,
  • Osama Rahma,
  • Michael Postow,
  • Ryan J. Sullivan,
  • Jason J. Luke,
  • Paolo A. Ascierto,
  • Iman Osman,
  • Tomas Kirchhoff

摘要

Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8+ T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.